Citalopram decreases agitation in the context of Alzheimer's disease, but at doses higher than those commonly prescribed and at the expense of side effects

Tools

Underwood, Benjamin R. and Fox, Chris (2014) Citalopram decreases agitation in the context of Alzheimer's disease, but at doses higher than those commonly prescribed and at the expense of side effects. BMJ Evidence-Based Medicine, 19 (5). p. 181. ISSN 2515-4478

Full text not available from this repository. (Request a copy)

Item Type:	Article
Additional Information:	Commentary on: Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease. The CitAD randomised clinical trial. JAMA 2014;311:682–91.
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Psychological Sciences (former - to 2018) Faculty of Medicine and Health Sciences > Research Groups > Mental Health Faculty of Science > Research Groups > Norwich Epidemiology Centre Faculty of Medicine and Health Sciences > Research Groups > Norwich Epidemiology Centre Faculty of Medicine and Health Sciences > Research Centres > Institute for Volunteering Research
Related URLs:	http://ebm.bmj.com/content/19/5/181.extr...
Depositing User:	Pure Connector
Date Deposited:	19 Oct 2015 15:00
Last Modified:	28 Mar 2025 06:51
URI:	https://ueaeprints.uea.ac.uk/id/eprint/54721
DOI:	10.1136/ebmed-2014-110016

Actions (login required)

View Item